異黏蛋白（MTDH）在轉(zhuǎn)移性乳腺癌中的表達(dá)及臨床意義
發(fā)布時(shí)間：2018-10-16 10:29
【摘要】：目的:通過(guò)分析異黏蛋白在乳腺癌原發(fā)灶、轉(zhuǎn)移灶中表達(dá)的情況,及其與乳腺癌生物學(xué)特征、生存時(shí)間的關(guān)系,推測(cè)異黏蛋白與乳腺癌的預(yù)后的關(guān)系。方法:1、選取2008年-2014年間于我院治療的可獲得病理切片的轉(zhuǎn)移性乳腺癌患者共74例。在74例轉(zhuǎn)移性乳腺癌患者中,有26例既有原發(fā)灶,又有轉(zhuǎn)移灶。其余的48例中24例只有原發(fā)灶,24例只有轉(zhuǎn)移灶。最終獲得轉(zhuǎn)移性乳腺癌原發(fā)灶組織50例、轉(zhuǎn)移灶組織50例和未發(fā)生轉(zhuǎn)移患者的原發(fā)灶組織50例,對(duì)其行MTDH免疫組化,對(duì)MTDH的表達(dá)情況進(jìn)行統(tǒng)計(jì)學(xué)分析。2、隨機(jī)選出50名未發(fā)生轉(zhuǎn)移的乳腺癌患者,對(duì)其原發(fā)灶行免疫組化,與上述原發(fā)灶MTDH的表達(dá)情況進(jìn)行統(tǒng)計(jì)學(xué)分析。3、統(tǒng)計(jì)患者相關(guān)資料,如年齡、月經(jīng)情況、激素水平、分子分型、腫塊大小、淋巴結(jié)轉(zhuǎn)移數(shù)目、無(wú)病生存期、總生存期,分析MTDH的表達(dá)與上述資料是否相關(guān)。推測(cè)MTDH在乳腺癌預(yù)后判斷中的作用和意義。結(jié)果:在50例原發(fā)灶及轉(zhuǎn)移灶中,MTDH在原發(fā)灶高表達(dá)的為37例,低表達(dá)為13例,在轉(zhuǎn)移灶中高表達(dá)的為46例,低表達(dá)為4例(P=0.031)。在26名患者原發(fā)灶及轉(zhuǎn)移灶中MTDH均高表達(dá)的為18例(69.3%),原發(fā)灶低表達(dá)轉(zhuǎn)移灶高表達(dá)為5例(19.2%),原發(fā)灶高表達(dá)轉(zhuǎn)移灶低表達(dá)為3例(11.5%),均低表達(dá)的為0例(0.0%)。在50例轉(zhuǎn)移性乳腺癌和非轉(zhuǎn)移性乳腺癌中,MTDH高表達(dá)的分別為24例、37例,低表達(dá)的分別為26例、13例(P0.05)。MTDH的表達(dá)情況與PR表達(dá)(P=0.029)有關(guān)。MTDH的表達(dá)影響預(yù)后,對(duì)于總生存期無(wú)影響。結(jié)論:1、在乳腺癌原發(fā)灶中,MTDH高表達(dá),預(yù)示容易發(fā)生轉(zhuǎn)移;2、PR表達(dá)呈陰性的乳腺癌患者,MTDH更傾向于高表達(dá);3、MTDH高表達(dá)與轉(zhuǎn)移部位無(wú)關(guān);4、在乳腺癌轉(zhuǎn)移灶中,MTDH高表達(dá),它可能成為未來(lái)治療的新靶點(diǎn);5、MTDH是乳腺癌DFS的獨(dú)立預(yù)后因素,但對(duì)于總生存期無(wú)影響。
[Abstract]:Objective: to analyze the expression of heteromucin in primary and metastatic lesions of breast cancer, and its relationship with biological characteristics and survival time of breast cancer, and to speculate the relationship between heteromycin and prognosis of breast cancer. Methods: 1. 74 patients with metastatic breast cancer treated in our hospital from 2008 to 2014 were selected. Of 74 patients with metastatic breast cancer, 26 had both primary and metastatic lesions. Of the remaining 48 cases, only primary lesions were found in 24 cases and metastatic lesions in 24 cases. Finally, 50 cases of primary tissues of metastatic breast cancer, 50 cases of metastatic tissues and 50 cases of non-metastatic breast cancer tissues were obtained. MTDH immunohistochemical staining was performed for them. The expression of MTDH was analyzed statistically. 2. 50 patients with breast cancer without metastasis were randomly selected, and their primary lesions were treated with immunohistochemistry. The expression of MTDH in the above primary tumor was analyzed statistically. 3. The relevant data of patients, such as age, were analyzed. Menstruation, hormone level, molecular classification, tumor size, lymph node metastasis, disease-free survival, total survival. The role and significance of MTDH in prognosis of breast cancer were speculated. Results: in 50 cases of primary tumor and metastasis, 37 cases were high expression of MTDH, 13 cases were low expression, 46 cases were high expression and 4 cases were low expression in primary tumor (P0. 031). There were 18 cases (69.3%) with high expression of MTDH, 5 cases (19.2%) with high expression of MTDH, 3 cases (11.5%) with low expression of MTDH and 0 cases (0.00%) with low expression of MTDH. In 50 cases of metastatic breast cancer and non-metastatic breast cancer, the high expression of MTDH was found in 24 cases, 37 cases and the low expression in 26 cases, respectively. The expression of). MTDH was related to the expression of PR (P0. 029) in 13 cases (P0.05). The expression of MTDH affected the prognosis, but had no effect on the overall survival time. Conclusion: 1, in primary breast cancer, the high expression of MTDH indicates that it is easy to metastasize; 2in breast cancer patients with negative PR expression, MTDH is more likely to be overexpression; 3MTDH high expression is not related to the location of metastasis; 4, in breast cancer metastasis, MTDH is highly expressed. MTDH is an independent prognostic factor for breast cancer DFS, but has no effect on overall survival.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R737.9
[Abstract]:Objective: to analyze the expression of heteromucin in primary and metastatic lesions of breast cancer, and its relationship with biological characteristics and survival time of breast cancer, and to speculate the relationship between heteromycin and prognosis of breast cancer. Methods: 1. 74 patients with metastatic breast cancer treated in our hospital from 2008 to 2014 were selected. Of 74 patients with metastatic breast cancer, 26 had both primary and metastatic lesions. Of the remaining 48 cases, only primary lesions were found in 24 cases and metastatic lesions in 24 cases. Finally, 50 cases of primary tissues of metastatic breast cancer, 50 cases of metastatic tissues and 50 cases of non-metastatic breast cancer tissues were obtained. MTDH immunohistochemical staining was performed for them. The expression of MTDH was analyzed statistically. 2. 50 patients with breast cancer without metastasis were randomly selected, and their primary lesions were treated with immunohistochemistry. The expression of MTDH in the above primary tumor was analyzed statistically. 3. The relevant data of patients, such as age, were analyzed. Menstruation, hormone level, molecular classification, tumor size, lymph node metastasis, disease-free survival, total survival. The role and significance of MTDH in prognosis of breast cancer were speculated. Results: in 50 cases of primary tumor and metastasis, 37 cases were high expression of MTDH, 13 cases were low expression, 46 cases were high expression and 4 cases were low expression in primary tumor (P0. 031). There were 18 cases (69.3%) with high expression of MTDH, 5 cases (19.2%) with high expression of MTDH, 3 cases (11.5%) with low expression of MTDH and 0 cases (0.00%) with low expression of MTDH. In 50 cases of metastatic breast cancer and non-metastatic breast cancer, the high expression of MTDH was found in 24 cases, 37 cases and the low expression in 26 cases, respectively. The expression of). MTDH was related to the expression of PR (P0. 029) in 13 cases (P0.05). The expression of MTDH affected the prognosis, but had no effect on the overall survival time. Conclusion: 1, in primary breast cancer, the high expression of MTDH indicates that it is easy to metastasize; 2in breast cancer patients with negative PR expression, MTDH is more likely to be overexpression; 3MTDH high expression is not related to the location of metastasis; 4, in breast cancer metastasis, MTDH is highly expressed. MTDH is an independent prognostic factor for breast cancer DFS, but has no effect on overall survival.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R737.9
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 楊晨晨;賀家勇;鄭樹濤;劉清;劉濤;戴芳;王棟;伊力亞爾·夏合丁;盧曉梅;;MTDH靶向RNA干擾質(zhì)粒構(gòu)建及其對(duì)食管癌細(xì)胞EC9706的影響[J];新疆醫(yī)科大學(xué)學(xué)報(bào);2015年11期
2 張玉洲;趙芳;徐高磊;江飛;孫少霖;馬守霞;肖華;;ER、PR、Her-2與VEGF在乳腺癌組織中的表達(dá)及其相互關(guān)系的研究進(jìn)展[J];醫(yī)學(xué)研究雜志;2015年02期
3 吳建珩;李曉輝;單嶠;李培棟;;星形膠質(zhì)細(xì)胞上調(diào)基因1和基質(zhì)金屬蛋白酶9在人腦膠質(zhì)瘤中的表達(dá)及其相關(guān)性研究[J];中國(guó)全科醫(yī)學(xué);2014年06期
4 張婷;楊軍;;星形細(xì)胞上調(diào)基因-1的研究進(jìn)展[J];基礎(chǔ)醫(yī)學(xué)與臨床;2014年01期
5 徐龍;劉兆U，
本文編號(hào)：2274074
本文鏈接：http://sikaile.net/yixuelunwen/zlx/2274074.html
最近更新
教材專著
